Guru Sonpavde, MD, of AdventHealth Cancer Institute, provides an overview of the trial data that led to the FDA approving nivolumab in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma, as well as the potential of this treatment option for patients who are ineligible for enfortumab vedotin plus pembrolizumab.
